These results suggest that the inhibition of Nrf2-HMOX1 through the ML385 drug combination aggravates the cisplatin-induced increase in the ROS burden and ferroptosis, thereby restoring the cisplatin sensitivity of cisplatin-resistant lung cancer cell lines. Here, HMOX1 is linked to lung carcinoma.